EudraCT number: 2005-000629-32
Sponsor: University of Oxford

A multicentre international study of capecitabine ± bevacizumab as adjuvant treatment of colorectal cancer.

QUASAR 2 is a study comparing 'standard' chemotherapy using capecitabine, against capecitabine + Avastin® (bevacizumab) with the expectation that adding bevacizumab to capecitabine may have the potential for improved relapse free and overall survival compared to capecitabine alone.

Summary of Results: 


Sponsor: University of Oxford & North West London Hospitals NHS Trust
Funded by: Cancer Research UK, Bobby Moore Fund www.cancerresearchuk.org

Conventional versus laparoscopic surgery for colorectal cancer within an enhanced programme.


Sponsors: University of Oxford & Royal Wolverhampton Hospitals NHS Trust
Funded by: Cancer Research UK The aim of the trial is to investigate the benefits of Iressa® (gefitinib) in halting or slowing the progression of oesophageal cancer after chemotherapy.



Dose Adaptation of Capecitabine Using Mobile Phone Toxicity Monitoring: A Pilot Study of Optimal Dose Scheduling of Capecitabine for Patients with Metastatic Colorectal or Metastatic Breast Cancer.

The aim of the study is to develop a system to manage side effects and adjust chemotherapy dose such that a patient can receive their personal maximum tolerated dose. This is a single centre, pilot study which will be run at the Churchill Hospital in Oxford.


Mobile Phone Project

Using GPRS mobile phone technology for managing symptoms associated with chemotherapy for colon cancer (The Mobile Phone Project)

The aim of the Mobile Phone Project was to develop a reliable and fully-tested system for managing symptoms associated with chemotherapy for colon cancer, using a mobile phone (provided by the Project) and supporting IT infra-structure.


Sponsor: University of Oxford
EudraCT number: 2009-016459-23
Funded by: GlaxoSmithKline
Endorsed by: Cancer Research UK

Phase II single arm multi-centre NCRI feasibility study of CHOP combined with Ofatumumab in induction and maintenance for patients with newly diagnosed Richter’s syndrome.  The study has been added to the NIHR CRN Portfolio database, study ID: 9476.

In the CHOP-OR trial, we are asking the following two questions:


Sponsor: University of Oxford
EudraCT number: 2009-016846-16

To determine the response rates and toxicity of 6MP with low dose methotrexate in patients with breast, ovarian, fallopian tube or primary serous peritoneal cancer who are known to have a BRCA mutation.

A Phase II Clinical trial in patients with known BRCA Defective Tumours.

6MP is closed to recruitment and is in follow-up.

Study Status

CLOSED to recruitment

Target recuitment:

71 (65 evaluable)


Sponsor: University of Oxford
Funded by: Cancer Research UK


Follow up of FOXFIRE patients and final database lock are now complete. Thank you to all sites for their support in reaching these milestones. 2017 will be an exciting year as the results of the study are analysed, presented and published.


EudraCT number: 2010-020621-40
Sponsor: University of Oxford
Funded by: Oxford Biomedical Research Centre

A Phase II Multi-Centre Randomised Controlled Study Of Nelfinavir Addition to Radiotherapy Treatment In Neo-Adjuvant Therapy for Rectal Cancer.

The chief aim of the trial is to investigate the safety and the activity of the radiosensitising drug, Nelfinavir, administered before and during radiotherapy in patients with rectal carcinoma.


About Us
We aim to enhance clinical and basic cancer research in Oxford with the ultimate goal of increasing cancer cure rates.
In Oxford, we have a great wealth of broad-ranging expertise and a powerful network of cancer researchers.
Study With Us
Our graduate training programmes for both scientists and clinicians are internationally recognised.
Subscribe to Department of Oncology RSS